Nihon House Holdings Co., Ltd. (1873)

Overview

Viva Biotech Holdings operates as an investment holding company providing a comprehensive suite of drug discovery services to biotechnology and pharmaceutical companies globally. With its foundation laid in 2008 and headquartered in Shanghai, China, the company harnesses structure-based drug discovery techniques to propel the research and development endeavors of its clientele. Its operations encompass a wide spectrum of services from discovery biology to chemistry services and antibody drug research and development. Additionally, Viva Biotech extends its expertise to contract development and manufacturing, offering an integrated platform for the progress of small molecule drugs from initial discovery through to commercialization. The company's commitment to fostering innovation is further exemplified by its provision of laboratory rental services, project management, and even equity for service arrangements, facilitating a conducive ecosystem for drug discovery and development.

Products and Services

• Discovery Biology Services:

  Encompasses protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics. This service line is foundational for understanding the structural and functional aspects of biomolecules, aiding in the identification of potential drug targets.

• Chemistry Services:

  Provides medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services. Viva Biotech's chemical services support the optimization of drug candidates through robust chemical synthesis and analysis.

• Antibody Drug Research and Development Services:

  Covers antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, and antibody cell line engineering transformation. The company utilizes advanced technology platforms like hybridoma, phage and yeast display, and others for the development of antibody-based drugs.

• Technology Platforms:

  Includes a variety of cutting-edge technologies such as VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS (Hydrogen/Deuterium Exchange Mass Spectrometry), crystal structure determination of protein, and SPR (Surface Plasmon Resonance) technology. These platforms enable Viva Biotech to offer innovative solutions and streamline the drug discovery process.

• Biological Materials:

  Offers cell lines, crystal structures, GPCR proteins, antibodies, and proteins, supplying essential biological components for research and development projects.

• Contract Development and Manufacturing Services:

  Specializes in the production of small molecule active pharmaceutical ingredients (APIs) and intermediates. This service facilitates the transition of drug candidates from the laboratory to manufacturing scale, supporting the commercialization process.

• Trading and Other Services:

  Engages in the trading of APIs, intermediates, and formulations, in addition to providing research service, laboratory rental services, project management, and bidding services. These offerings are designed to meet the diverse needs of Viva Biotech's clients, ranging from early-stage startups to established pharmaceutical companies.